NasdaqGS:RAREBiotechs
Ultragenyx (RARE) Is Up 17.6% After ESOP Share Shelf And Conference Spotlight On Gene Therapies – Has The Bull Case Changed?
In June 2026, Ultragenyx Pharmaceutical Inc. filed a US$81.53 million shelf registration for 3,400,000 common shares linked to an employee stock ownership plan and participated in the Goldman Sachs 47th Annual Global Healthcare Conference, where Founder and CEO Emil D. Kakkis presented the company's rare disease and gene therapy focus.
These developments come alongside growing attention on Ultragenyx’s gene therapy pipeline and regulatory tailwinds, which are reshaping how investors assess...